MDA
MDA Space Ltd
MDA trails on the overall score without a compensating advantage in the available component scores.
NVDA
NVIDIA Corporation
NVDA has the edge over MDA overall, supported by stronger fundamentals and stronger valuation.
MDA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Weak | |
| Strong |
MDA's revenue and balance sheet are currently healthy, and its profitability is stable, but its cash flow is weak.
NVDA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
NVDA's revenue, profitability, cash flow and balance sheet are all currently strong.
MDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 28x | $29.16 | — |
| Cheap | 49x | $27.91 | -4.3% |
| Fair | 51x | $28.95 | -0.7% |
| Current | 51x | $29.16 | — |
| Expensive | 57x | $32.29 | +11% |
Historical ranges are pointers, not guarantees.
MDA's PE is 51x, but its earnings don't support one, so it isn't a reliable read right now.
NVDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $166 | — |
| Current | 21x | $166 | — |
| Cheap | 44x | $345 | +108% |
| Fair | 65x | $511 | +207% |
| Expensive | 93x | $734 | +342% |
Historical ranges are pointers, not guarantees.
NVDA has the edge over MDA in the historical PE scenario, which offers more potential upside but is not a forecast.
MDA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Strong growth | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for MDA, but weaker profitability. However, they disagree widely on these estimates.
NVDA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Broad | |
| Moderate |
Analysts expect strong earnings and revenue growth for NVDA, but weaker profitability.
MDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.06 | +85% |
| Q2 2026 | $0.57 | -14% |
| Q1 2026 | $0.59 | +3.5% |
| Q4 2025 | $0.61 | +30% |
| Q3 2025 | $0.61 | +49% |
| Q2 2025 | $0.66 | +128% |
| Q1 2025 | $0.57 | +104% |
| Q4 2024 | $0.47 | +57% |
| Q3 2024 | $0.41 | +52% |
MDA earned $0.57 per share over the past year, down 14% from the year before.
NVDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.77 | +74% |
| Q3 2026 | $7.91 | +125% |
| Q2 2026 | $6.53 | +111% |
| Q1 2026 | $4.90 | +67% |
| Q4 2025 | $4.03 | +59% |
| Q3 2025 | $3.51 | +65% |
| Q2 2025 | $3.10 | +81% |
| Q1 2025 | $2.94 | +147% |
| Q4 2024 | $2.54 | +234% |
NVDA has the edge over MDA on earnings, with more consistent year-over-year improvement.
MDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $351M | +28% |
| Q1 2026 | $333.7M | +37% |
| Q4 2025 | $363.4M | +51% |
| Q3 2025 | $294.2M | +41% |
| Q2 2025 | $274.2M | +55% |
| Q1 2025 | $243.9M | +58% |
| Q4 2024 | $240.9M | +56% |
| Q3 2024 | $208.7M | +39% |
MDA's revenue has grown year over year every quarter since early 2022: $351M last quarter, up 28% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 4.5% | -5.8 points |
| Q1 2026 | 7% | -3.1 points |
| Q4 2025 | 6.4% | +0.3 points |
| Q3 2025 | 3.9% | -5 points |
| Q2 2025 | 10% | +5.7 points |
| Q1 2025 | 10% | +6.7 points |
| Q4 2024 | 6.1% | +5.3 points |
| Q3 2024 | 8.9% | +4 points |
MDA's operating margin was 4.5% last quarter, down 5.8 points from the same quarter a year ago.
NVDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $96.2B | +106% |
| Q2 2026 | $81.6B | +85% |
| Q1 2026 | $68.1B | +73% |
| Q4 2025 | $57B | +62% |
| Q3 2025 | $46.7B | +56% |
| Q2 2025 | $44.1B | +69% |
| Q1 2025 | $39.3B | +78% |
| Q4 2024 | $35.1B | +94% |
NVDA has the edge over MDA on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +5.4 points |
| Q2 2026 | 66% | +17 points |
| Q1 2026 | 65% | +3.9 points |
| Q4 2025 | 63% | +0.8 points |
| Q3 2025 | 61% | -1.2 points |
| Q2 2025 | 49% | -16 points |
| Q1 2025 | 61% | -0.5 points |
| Q4 2024 | 62% | +4.9 points |
NVDA has the edge over MDA on profitability, with a higher operating margin.
MDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$102.4M | -2464% |
| Q1 2026 | -$4.5M | -102% |
| Q4 2025 | $11.7M | -95% |
| Q3 2025 | -$12.2M | -107% |
| Q2 2025 | $4.3M | -95% |
| Q1 2025 | $205.3M | +$207M |
| Q4 2024 | $230.2M | +$297M |
| Q3 2024 | $164.1M | +$213.5M |
MDA's free cash flow was −$107M over the past year, against $604M the year before.
NVDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $21.4B | +59% |
| Q2 2026 | $48.6B | +86% |
| Q1 2026 | $34.9B | +124% |
| Q4 2025 | $22.1B | +32% |
| Q3 2025 | $13.5B | -0.3% |
| Q2 2025 | $26.2B | +75% |
| Q1 2025 | $15.6B | +38% |
| Q3 2024 | $13.5B | +113% |
NVDA has the edge over MDA on cash generation, producing positive trailing cash flow while its opponent burns cash.
MDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7.4% | +9.8M shares |
| 1 year | +11% | +14.5M shares |
| 3 years | +19% | +22.3M shares |
| 5 years | +20% | +23.8M shares |
MDA has 143M diluted shares, up 11% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
MDA hasn't bought back shares in the past year.
NVDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -106M shares |
| 1 year | -1% | -247M shares |
| 3 years | -2.8% | -705M shares |
| 5 years | -4.1% | -1B shares |
| Available history | -1.8% | -435M shares |
NVDA has the edge over MDA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $19.7B |
| Q2 2026 | $19.3B |
| Q1 2026 | $3.8B |
| Q4 2025 | $12.5B |
| Q3 2025 | $9.7B |
| Q2 2025 | $14.1B |
| Q1 2025 | $7.8B |
| Q4 2024 | $11B |
NVDA spent $55.3B buying back its own shares over the past year, up 30% from the year before.
MDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -0.1x | Net Cash |
| Q1 2026 | -0.6x | Net Cash |
| Q4 2025 | 1.0x | Very low |
| Q3 2025 | 0.9x | Very low |
| Q2 2025 | -1.1x | Net Cash |
| Q1 2025 | -1.0x | Net Cash |
| Q4 2024 | -0.2x | Net Cash |
| Q3 2024 | 1.7x | Healthy |
MDA has the edge over NVDA on leverage, with a lower net debt burden relative to earnings.
NVDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -0.0x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.0x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.0x | Very low |
| Q4 2024 | -0.0x | Net Cash |
NVDA's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
MDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.1 | Neutral |
| Stochastic | 22.8 | Neutral |
MDA's weekly RSI is 46 (neutral) and its Stochastic is 23 (neutral).
NVDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 18.1 | Oversold |
NVDA's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
MDA PE vs Technology Sector
| Metric | MDA | Sector median | Relative |
|---|---|---|---|
| PE | 51x | 28x | 84% above |
| PE % | 58 | 18 | 40 pts above |
MDA is trading at 51x earnings, a 84% premium to the Technology sector's median of 28x, though its earnings don't support one.
NVDA PE vs Technology Sector
| Metric | NVDA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 28x | 25% below |
| PE % | 0 | 35 | 35 pts below |
NVDA has the edge over MDA on valuation relative to its sector.
MDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $28.8 | 1.4% above |
| 20 week MA | $30.7 | 4.9% below |
MDA has stronger trend alignment. MDA is above 1 of 2 weekly averages versus NVDA above 1 of 5.
NVDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $208.9 | 20% below |
| 20 week MA | $212.0 | 22% below |
| 50 week MA | $199.9 | 17% below |
| 100 week MA | $175.1 | 5.1% below |
| 200 week MA | $123.6 | 34% above |
NVDA has fallen below most of its moving averages, though it's still 34% above its 200-week average.
MDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2026 YTD | $29.1 | $29.2 | +0.1% |
MDA has the edge over NVDA on returns for 2026, with the stronger performance.
NVDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.92 | $13.0 | +119% |
| 2021 | $13.0 | $29.6 | +128% |
| 2022 | $29.6 | $15.2 | -49% |
| 2023 | $15.2 | $49.5 | +226% |
| 2024 | $49.5 | $137.0 | +177% |
| 2025 | $137.0 | $190.5 | +39% |
| 2026 YTD | $190.5 | $166.2 | -13% |
NVDA's yearly returns have swung widely, from +226% in 2023 to −49% in 2022. It's down 13% so far in 2026.